Compare · BDX vs IRMD
BDX vs IRMD
Side-by-side comparison of Becton Dickinson and Company (BDX) and iRadimed Corporation (IRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and IRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 46.2x IRMD ($1.14B).
- Over the past year, BDX is up 0.3% and IRMD is up 18.4% - IRMD leads by 18.1 points.
- BDX has hit the wire 8 times in the past 4 weeks while IRMD has been quiet.
- BDX has more recent analyst coverage (25 ratings vs 2 for IRMD).
- Company
- Becton Dickinson and Company
- iRadimed Corporation
- Price
- $191.68-1.09%
- $88.42-1.22%
- Market cap
- $52.78B
- $1.14B
- 1M return
- +5.72%
- +6.70%
- 1Y return
- +0.32%
- +18.41%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 2
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
iRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest IRMD
- Director Kiani Joe E converted options into 698 shares (SEC Form 4)
- IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
- Needham initiated coverage on iRadimed
- Director Allen Monty K sold $122,622 worth of shares (1,419 units at $86.41), decreasing direct ownership by 7% to 19,581 units (SEC Form 4)
- SEC Form 144 filed by iRadimed Corporation
- Amendment: iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Other Events
- SEC Form 10-Q filed by iRadimed Corporation
- iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
- IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026